Novavax Stock Still Has A Solid Chance

InvestorPlace2022-01-13

The Covid-19 pandemic has worked in the favor of pharmaceutical companies. Many have become hot picks today. Although Novavax(NASDAQ:NVAX) hasn’t had a smooth ride lately, there is a lot to look ...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/1144288118?lang=zh_CN&edition=full","thumbnail":"","is_english":true,"pubTime":"2022-01-13 13:22","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1144288118","market":"us","top_or_hot":-1,"title":"Novavax Stock Still Has A Solid Chance","media":"InvestorPlace","content":"<div>\n<p>The Covid-19 pandemic has worked in the favor of pharmaceutical companies. Many have become hot picks today. Although Novavax(NASDAQ:NVAX) hasn’t had a smooth ride lately, there is a lot to look ...</p>\n\n<a href=\"https://investorplace.com/2022/01/nvax-stock-still-has-a-solid-chance-at-being-a-vaccine-race-winner/\">网页链接</a>\n\n</div>\n","source":"lsy1606302653667","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Novavax Stock Still Has A Solid Chance</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNovavax Stock Still Has A Solid Chance\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-01-13 13:22 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://investorplace.com/2022/01/nvax-stock-still-has-a-solid-chance-at-being-a-vaccine-race-winner/><strong>InvestorPlace</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The Covid-19 pandemic has worked in the favor of pharmaceutical companies. Many have become hot picks today. Although Novavax(NASDAQ:NVAX) hasn’t had a smooth ride lately, there is a lot to look ...</p>\n\n<a href=\"https://investorplace.com/2022/01/nvax-stock-still-has-a-solid-chance-at-being-a-vaccine-race-winner/\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"NVAX","symbol_name":"诺瓦瓦克斯医药","start_time":0,"source_url":"https://investorplace.com/2022/01/nvax-stock-still-has-a-solid-chance-at-being-a-vaccine-race-winner/","article_id":"1144288118","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1144288118","pubTimestamp":1642051328,"sourceInfo":{"source_id":"lsy1606302653667","name":"InvestorPlace"},"weMediaInfo":null,"summary":"The Covid-19 pandemic has worked in the favor of pharmaceutical companies. Many have become hot pick","collect":0,"end_time":0,"defaultTopTitle":"investorplace.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"NVAX":"诺瓦瓦克斯医药"},"translate_title":"诺瓦瓦克斯医药股票仍有坚实的机会","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NVAX":0.9},"content_text":"The Covid-19 pandemic has worked in the favor of pharmaceutical companies. Many have become hot picks today. Although Novavax(NASDAQ:NVAX) hasn’t had a smooth ride lately, there is a lot to look forward to. Investors tend to think that the current surge in Covid-19 cases across the globe could mean an end of the pandemic shortly but this may not be the case. Despite the dip in NVAX stock in 2021, it could have a stellar 2022.The stock has dipped significantly over the past six months and is currently trading much lower than its all-time high. There haven’t been any major company announcements or significant events that could’ve led to this decline in the price. Therefore, it stems from investors’ lack of enthusiasm towards the company’s prospects.This might change in 2022. NVAX stock is trading at $130 and could inch closer to $150 soon.Here are two reasons I think the stock will move upwards.Vaccine Demand Could ExplodeDespite the rise in coronavirus cases across the globe, the cases are milder and the hospitalization rates are lower. The good news is that it could lead to lower deaths and a higher recovery rate.However, this does not change the vaccine scenario. The demand for vaccines is not going to decline anytime soon and if the current surge continues, we could see a rise in demand.Once an early favorite, Novavax took too long to file for Emergency Use Authorization (EUA) in the U.S. due to manufacturing and technical issues. This in turn led to the consistent dip in the stock throughout 2021.Since the Food and Drug Administration (FDA) allows the mixing of vaccines, there will still be a demand for Novavax as a booster. It could give a huge lift to the company and will allow it to gain a larger market share.The demand for vaccines will be a key factor for the company. If it can meet the demands by increasing the manufacturing capacity, it will be able to generate massive revenue.On these metrics alone, NVAX stock could be a winner this year.It is also important to keep in mind that the company only recently got authorizations from different countries and this will reflect in the bottom line for the next quarter.Novavax Is Getting Approvals From Different CountriesNovavax already has authorization in 31 countries and this is no small feat.The company is working towards supplying more than200 million doses to EU countries alone. They expect a European Union EUA for their vaccine in the next few months which could take the stock higher.Thanks to these international authorizations, Novavax does not depend on any single country, like the United States, for revenue. It can manage to generate solid revenue by providing vaccines to developing countries and the European Union. The first-quarter numbers will be important for the investors as they will speak about the production capacity and the deliveries of the vaccine.Novavax’s vaccine data is positive. And if it manages to roll out the vaccines on time, NVAX stock will go even higher.The Bottom Line On NVAX StockThe next quarter for the company could be huge and it could start generating strong revenue very soon.There is always a risk when a stock is heavily dependant on a single product but if the company manages to move at the right time and gets the authorization, it could beat analyst projections.NVAX stock is trading at a discount currently and the coming quarter could take it to a new high.If the pandemic becomes endemic in the near future, we will regularly need vaccines and this is when Novavax will finally be a winner in the vaccine race.","kind":null,"is_publish_news":null,"is_publish_highlight":null,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":9,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1144288118"}